A Multi-center, Randomized, Positive-controlled Phase 2 Clinical Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of WX-081 in Participants With Drug-naive&Susceptible or Drug-Resistant Pulmonary Tuberculosis
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Sudapyridine (Primary) ; Antituberculars; Bedaquiline
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Acronyms WX-081
- Sponsors Shanghai Jiatan Pharmatech
- 03 Apr 2023 Status changed from recruiting to completed.
- 14 Dec 2021 Status changed from not yet recruiting to recruiting.
- 06 Nov 2020 New trial record